MSYS.L

Microsaic Systems Plc
Microsaic Systems - Completion of Acquisition
25th January 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8360A
Microsaic Systems plc
25 January 2024
 

25 January 2024

Microsaic Systems plc

("Microsaic" or the "Company")

 

Completion of Acquisition

 

Capitalised terms in this announcement carry the same meaning as in the Circular
or subsequent announcements, unless the context indicates otherwise

 

Microsaic Systems plc (AIM: MSYS), the developer of micro-electronic instruments and analytical solutions, announces that, further to the announcement made by the Company on 12 January 2024 (RNS No. 5915Z)1, it has completed the acquisition of the Modern Water assets and the Microtox® water testing business previously owned by DeepVerge plc.

 

Bob Moore, Acting Executive Chairman, commented:

 

"This concludes our recent corporate activity to recapitalise Microsaic on an enlarged basis by integrating the Modern Water Microtox® water testing business. We are now in the process of installing the acquired equipment in newly leased and lower cost laboratory space in York, England. We intend to restart sales and manufacture of water testing reagents as soon as reasonably practicable, to meet continuing demand from the installed base of Microtox® users.

 

Additionally, we remain focused on supplying and servicing to customers operating Microsaic's mass spectrometry units, through our existing outsourced manufacturing partner and a newly appointed outsourced servicing partner. We are committed to supporting existing clients and prospective distribution partners in assessing the ProteinID and PFAS2 units ahead of planned field trials expected in H1 2024, designed to assess their performance in monitoring biomanufacturing of drugs and the detection of 'forever chemicals'."

 

 

1            https://www.londonstockexchange.com/news-article/MSYS/acquisition-update-change-of-registered-office/16287737

 2           PFAS are Perfluoroalkl and Polyfluoroalkyl synthetic chemicals which have potentially carcinogenic properties and don't naturally break down hence called 'forever chemicals'.

 

Enquiries:

Microsaic Systems plc

Bob Moore, Acting Executive Chairman

+44 (0) 20 3657 0050

via TPI

 

 

Singer Capital Markets
(Nominated Adviser & Joint Broker)

Aubrey Powell / Angus Campbell / Oliver Platts

+44 (0)20 7496 3000

 

 

Turner Pope Investments (TPI) Limited
(Joint Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

About Microsaic Systems

Microsaic has over 20 years' experience in microelectronics and development of instrumentation. The Company has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application serving markets in diversified Industries, Human and Environmental Health. Microsaic's system solutions have enabled analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous detection of data at multiple steps in the process workflow.

 

Microsaic's products and solutions are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQQKQBPDBKBPDB]]>
TwitterFacebookLinkedIn